Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

81. Heparin-Induced Thrombocytopenia. (PubMed)

Heparin-Induced Thrombocytopenia. 26535527 2015 11 06 2018 12 02 1533-4406 373 19 2015 11 05 The New England journal of medicine N. Engl. J. Med. Heparin-Induced Thrombocytopenia. 1883 10.1056/NEJMc1510993 Hoover Jon J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Antithrombins 0 Pipecolic Acids 9005-49-6 Heparin AIM IM N Engl J Med. 2015 Jul 16;373(3):252-61 26176382 N Engl J Med. 2015 Nov 5;373(19):1883-4 26535525 Antithrombins therapeutic use Female Heparin adverse

Full Text available with Trip Pro

2015 NEJM

82. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT)

A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT) A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis

2015 NIHR HTA programme

83. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. (PubMed)

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. Conflicting evidence exists on the efficacy and safety of bivalirudin administered as part of percutaneous coronary intervention (PCI) in patients with an acute coronary syndrome.We randomly assigned 7213 patients with an acute coronary syndrome for whom PCI was anticipated to receive either bivalirudin or unfractionated heparin. Patients in the bivalirudin group were subsequently randomly assigned to receive or not to receive (...) a post-PCI bivalirudin infusion. Primary outcomes for the comparison between bivalirudin and heparin were the occurrence of major adverse cardiovascular events (a composite of death, myocardial infarction, or stroke) and net adverse clinical events (a composite of major bleeding or a major adverse cardiovascular event). The primary outcome for the comparison of a post-PCI bivalirudin infusion with no post-PCI infusion was a composite of urgent target-vessel revascularization, definite stent

Full Text available with Trip Pro

2015 NEJM

84. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. (PubMed)

Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. A daily injection of low-molecular-weight heparin (LMWH) is often prescribed to women with unexplained recurrent pregnancy loss (RPL), although evidence suggesting a benefit is questionable.To determine whether LMWH increases ongoing pregnancy and live-birth rates in women with unexplained RPL.Controlled, multicenter trial with randomization using

2015 Annals of Internal Medicine

85. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. (PubMed)

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. The safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain.To determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during (...) primary PCI.Multicenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013.Patients were randomly assigned to receive bivalirudin with a post-PCI infusion (n = 735), heparin alone (n = 729), or heparin plus tirofiban with a post-PCI infusion (n = 730). Among patients treated with bivalirudin, a postprocedure 1.75 mg/kg/h infusion was administered for a median of 180 minutes (IQR, 148-240 minutes).The primary end point

Full Text available with Trip Pro

2015 JAMA

86. Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery. (PubMed)

Association between perioperative low-molecular-weight heparin vs unfractionated heparin and clinical outcomes in patients with cancer undergoing surgery. In patients with cancer undergoing surgery, what is the association between perioperative thromboprophylaxis with low-molecular-weight heparin (LMWH) or unfractionated heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding outcomes?When used for perioperative thromboprophylaxis (...) , there are no differences in the association of LMWH vs unfractionated heparin for preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or thrombocytopenia in patients with cancer.

2015 JAMA

87. Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The BRIGHT Randomized Clinical Trial. (PubMed)

Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The BRIGHT Randomized Clinical Trial. The safety and efficacy of bivalirudin compared with heparin with or without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI) are uncertain.To determine if bivalirudin is superior to heparin alone and to heparin plus tirofiban during (...) primary PCI.Multicenter, open-label trial involving 2194 patients with AMI undergoing primary PCI at 82 centers in China between August 2012 and June 2013.Patients were randomly assigned to receive bivalirudin with a post-PCI infusion (n = 735), heparin alone (n = 729), or heparin plus tirofiban with a post-PCI infusion (n = 730). Among patients treated with bivalirudin, a postprocedure 1.75 mg/kg/h infusion was administered for a median of 180 minutes (IQR, 148-240 minutes).The primary end point

Full Text available with Trip Pro

2015 JAMA

88. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system (PubMed)

Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system To characterize heparin-induced thrombocytopenia (HIT) at a single pediatric center including the prevalence and the accuracy of the 4Ts scoring system as a predictor of HIT.In this retrospective cohort study, we identified 155 consecutive patients <21 years old with sufficient data for 4Ts scoring. The 4Ts scoring system is a validated pretest tool in adults that predicts (...) the likelihood of HIT using clinical features. Hospital-wide exposure to unfractionated and low molecular weight heparin was determined by querying the hospital pharmacy database.The majority of patients with suspected HIT (61.2%) were on surgical services. Prediction of HIT risk using initial 4Ts scoring found 3 (2%) had high risk 4Ts scores, 114 (73%) had intermediate risk 4Ts scores, and the remaining 38 (25%) had low risk 4Ts scores. HIT was confirmed in 0/38 patients with low risk 4Ts scores, 2/114

Full Text available with Trip Pro

2015 EvidenceUpdates

89. Unfractionated Heparin and Low-Molecular-Weight Heparin

Unfractionated Heparin and Low-Molecular-Weight Heparin © 2013 Thrombosis Canada. Page 1 of 5 UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients. ABBREVIATIONS: ALT alanine aminotransferase aPTT activated partial thromboplastin time AST aspartate aminotransferase AT antithrombin CBC complete blood count HIT heparin (...) -induced thrombocytopenia INR international normalized ratio IV intravenous LMWH low-molecular-weight heparin MI myocardial infarction PT prothrombin time TNK tenecteplase tPA tissue plasminogen activator UFH unfractionated heparin U units VTE venous thromboembolism MECHANISM OF ACTION: Unfractionated heparin (UFH) acts as an anticoagulant by forming a complex with antithrombin (AT) catalysing the inhibition of several activated blood coagulation factors: thrombin (factor IIa), factor IXa, Xa, XIa

2015 Thrombosis Interest Group of Canada

90. Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. (PubMed)

Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. Fondaparinux was associated with reduced major bleeding events and improved survival compared with low-molecular-weight heparin (LMWH) in a large randomized clinical trial involving patients with non-ST-segment elevation myocardial infarction (NSTEMI). Large-scale experience of the use of fondaparinux vs LMWH in a nontrial setting

Full Text available with Trip Pro

2015 JAMA

91. Randomised controlled trial: Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy

Randomised controlled trial: Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy Article

2015 Evidence-Based Medicine (Requires free registration)

92. Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated Patients in the ICU

Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated Patients in the ICU "Nebulized Heparin for Adjunctive Treatment of Mechanically Ventilated " by Phoebe Robinson < > > > > > Title Author Date of Graduation Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Acute lung injury (ALI) is a serious clinical concern (...) brought on by inflammatory triggers and is characterized by rapid onset of respiratory distress in the setting of inflammatory insult. Fibrin deposition from the inflammation leads to poor ventilation and perfusion. There is no current treatment for ALI other than supportive measures. Heparin is an anticoagulant that prevents fibrin deposition. Previous animal and ALI model studies have demonstrated improvement in lung function markers with nebulized heparin. This review looks at the effects

2015 Pacific University EBM Capstone Project

93. Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial (PubMed)

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial Venous thromboembolism (VTE) is common in cancer patients. Evidence has suggested that low molecular weight heparin (LMWH) might improve survival in patients with cancer by preventing both VTE and the progression of metastases. No trial in a single cancer type has been powered to demonstrate a clinically significant survival difference. The aim of this trial

Full Text available with Trip Pro

2015 EvidenceUpdates

94. PROPATEN heparin-bonded vascular graft for peripheral arterial disease

PROPATEN heparin-bonded vascular graft for peripheral arterial disease PR PROP OPA ATEN heparin-bonded vascular gr TEN heparin-bonded vascular graft for aft for peripher peripheral arterial disease al arterial disease Medtech innovation briefing Published: 13 October 2015 nice.org.uk/guidance/mib42 pathways Summary Summary The Gore PROPATEN heparin-bonded vascular graft is a synthetic graft used to treat peripheral arterial disease by bypassing damaged blood vessels. The graft is made from (...) expanded polytetrafluoroethylene (ePTFE) that has a layer of heparin anticoagulant bonded to its inner surface, which is designed to reduce graft occlusion. Relevant evidence was limited and consisted of 1 randomised controlled trial and 5 cohort studies, with either artificial graft or autologous vein graft comparators. The reports indicate that the PROPATEN graft is either equivalent or inferior to autologous vein grafts in maintaining patency (that is, remaining open and functional over time

2015 National Institute for Health and Clinical Excellence - Advice

95. Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study (PubMed)

Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings

Full Text available with Trip Pro

2014 EvidenceUpdates

96. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. (PubMed)

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. Venous thromboembolism (VTE) is a common complication of acute illness, and its prevention is a ubiquitous aspect of inpatient care. A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference (...) in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin.To evaluate the comparative cost-effectiveness of LMWH vs UFH for prophylaxis against VTE in critically ill patients.Prospective economic evaluation concurrent with the Prophylaxis for Thromboembolism in Critical Care Randomized Trial (May 2006 to June 2010). The economic evaluation adopted a health care payer

Full Text available with Trip Pro

2014 JAMA

97. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. (PubMed)

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients. Venous thromboembolism (VTE) is a common complication of acute illness, and its prevention is a ubiquitous aspect of inpatient care. A multicenter blinded, randomized trial compared the effectiveness of the most common pharmocoprevention strategies, unfractionated heparin (UFH) and the low-molecular-weight heparin (LMWH) dalteparin, finding no difference (...) in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus and heparin-induced thrombocytopenia among critically ill medical-surgical patients who received dalteparin.To evaluate the comparative cost-effectiveness of LMWH vs UFH for prophylaxis against VTE in critically ill patients.Prospective economic evaluation concurrent with the Prophylaxis for Thromboembolism in Critical Care Randomized Trial (May 2006 to June 2010). The economic evaluation adopted a health care payer

Full Text available with Trip Pro

2014 JAMA

98. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. (PubMed)

Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention (PCI). We aimed to define the effects of a bivalirudin-based anticoagulation regimen compared with a heparin-based anticoagulation regimen on ischaemic and bleeding outcomes.We searched Medline, the Cochrane Library, and relevant meeting abstracts (search done (...) on April 9, 2014) for randomised trials that assessed bivalirudin versus heparin in patients planned for PCI. The primary efficacy endpoint was the incidence of major adverse cardiac events (MACE) up to 30 days. Secondary efficacy endpoints were death, myocardial infarction, ischaemia-driven revascularisation, and stent thrombosis. The primary safety endpoint was major bleeding up to 30 days. We calculated pooled risk ratios and 95% CIs using random-effects models.We included data from 16 trials

2014 Lancet

99. Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity. (PubMed)

Slow versus fast subcutaneous heparin injections for prevention of bruising and site-pain intensity. Heparin is an anticoagulant medication that is normally injected subcutaneously. Subcutaneous administration of heparin may result in complications such as bruising, haematoma and pain at the injection site. One of the factors that may affect pain, haematoma and bruising is injection speed.To assess the effects of the duration (speed) of subcutaneous heparin injection on pain, haematoma (...) and bruising at the injection site in people admitted to hospitals or clinics who require treatment with unfractionated heparin or low molecular weight heparin.The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched August 2013) and CENTRAL (2013, Issue 7). We searched MEDLINE, EMBASE, CINAHL and two Persian databases Iranmedex and SID (August 2013).We sought randomised controlled trials (RCTs) comparing the effects of different durations

2014 Cochrane

100. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. (PubMed)

Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Since hypercoagulability might result in recurrent miscarriage, anticoagulant agents could potentially increase the chance of live birth in subsequent pregnancies in women with unexplained recurrent miscarriage, with or without inherited thrombophilia.To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two (...) , unfractionated heparin (UFH), and low molecular weight heparin (LMWH) for the prevention of miscarriage. One treatment could be compared with another or with no-treatment (or placebo).Two review authors (PJ and SK) assessed the studies for inclusion in the review and extracted the data. If necessary they contacted study authors for more information. We double checked the data.Nine studies, including data of 1228 women, were included in the review evaluating the effect of either LMWH (enoxaparin or nadroparin

2014 Cochrane